Table 3.
Efficacy parameters in 47 participants with migraine during treatment periods of 12 weeks. Figures are means (SD)
| Lisinopril | Placebo | Mean % reduction (95% CI) | |
|---|---|---|---|
| Primary efficacy parameter | |||
| Hours with headache | 129 (125) | 162 (142) | 20 (5 to 36) |
| Days with headache | 19.7 (14) | 23.7 (11) | 17 (5 to 30) |
| Days with migraine | 14.5 (11) | 18.5 (10) | 21 (9 to 34) |
| Secondary efficacy parameter | |||
| Headache severity index | 297 (325) | 370 (310) | 20 (3 to 37) |
| Triptan doses | 15.7 (15) | 20.2 (17) | 22 (7 to 38) |
| Doses of analgesics | 14.5 (23) | 16.2 (20) | 11 (−16 to 37) |
| Days with sick leave | 2.30 (4.32) | 2.09 (2.50) | −10 (−64 to 37) |
| Bodily pain* | 63.7 (29) | 53.8 (23) | −18 (−35 to −1) |
| General health* | 73.6 (20) | 74.1 (21) | 1 (−6 to 7) |
| Vitality* | 61.1 (24) | 58.2 (21) | −5 (−18 to 8) |
| Social functioning* | 81.4 (25) | 79.5 (23) | −2 (−11 to 6) |
*
From SF-36.